Why Fatty Liver Often Goes Undetected and When to Seek Evaluation

Most people who have fatty liver disease have no idea. There is no pain, no obvious symptom, no moment where something feels wrong. That is exactly what makes it so concerning, and exactly why understanding your risk matters.

At Kentuckiana Medicine, Dr. Cruz and our team regularly work with patients who are surprised to learn they may have a condition affecting their liver. The good news is that when it is caught early, there is a great deal that can be done.

It Is More Common Than You Think and Almost Always Silent

Non-alcoholic Fatty Liver Disease, or NAFLD, occurs when excess fat accumulates in the liver in people who drink little or no alcohol. More than 80 million Americans are estimated to have it, but only about 6% are aware. In most cases, it is discovered by accident during a scan ordered for something else. In roughly 70% of cases, standard liver enzyme tests come back completely normal, meaning most patients never receive a follow-up workup at all.

If you have type 2 diabetes, prediabetes, obesity, or cardiovascular risk factors, your likelihood of having NAFLD is significantly higher than the general population. Studies have found that more than 70% of patients with type 2 diabetes also have NAFLD, and that figure climbs above 90% when BMI exceeds 35.

What Happens If It Goes Unaddressed

Fatty liver disease exists on a spectrum. On one end is simple fat accumulation in the liver, which may remain stable for years. On the other end is a more serious form called NASH, or Non-Alcoholic Steatohepatitis, which involves inflammation and progressive liver damage. Advanced NASH can lead to fibrosis, cirrhosis, and liver cancer.

NAFLD is also closely linked to insulin resistance, type 2 diabetes, blood vessel dysfunction, and heart disease. Much like high blood pressure, it tends to be silent until it is not, and by the time symptoms appear, the window for early intervention has often passed.

How Do You Know If You Should Be Tested

Because standard blood work often misses fatty liver disease, a more targeted approach is needed for patients at higher risk. One of the most useful tools available is the FIB-4 index, an FDA-recognized scoring system calculated using four values your doctor likely already has: your age, AST level, platelet count, and ALT level. The result places you in a low, intermediate, or high risk category for liver fibrosis. A FibroScan, which uses specialized ultrasound to assess liver stiffness, is another affordable and noninvasive way to get a clearer picture.

At Kentuckiana Medicine, we can help you understand where you stand and what your results actually mean for your long-term health.

There Are Real Options But Timing Matters

There are currently no FDA-approved medications specifically for NAFLD or NASH, but that does not mean you are without options. Evidence-based approaches include lifestyle intervention, structured weight loss, and cardiovascular risk reduction. Certain medications approved for type 2 diabetes and weight management, including GLP-1 agonists, have also shown effectiveness in slowing progression.

At Kentuckiana Medicine, our approach may also include IV Alpha Lipoic Acid, IV Plaquex, supportive liver supplements, and dietary guidance tailored to your situation. Dr. Cruz works with each patient individually to determine what makes the most sense based on their health history, risk factors, and goals.

This Is Worth a Conversation and Here Is How to Start

You don’t need to experience symptoms before seeking evaluation. In fact, waiting for symptoms is part of what allows this condition to progress unnoticed in so many people. If you have type 2 diabetes, prediabetes, obesity, elevated liver enzymes, or cardiovascular risk factors, finding out where you stand now is one of the most proactive things you can do for your health.

Dr. Cruz and the team at Kentuckiana Medicine are ready to help you do exactly that. One conversation could change what your liver looks like ten years from now.